The international market for insulin delivery devices remains highly competitive with at least six major producers currently dominating the trade, according to Transparency Market Research, which predicts continued growth over the next eight years. Read More »

Ionis Pharmaceuticals Inc. will retain all rights to inotersen and IONIS-FB-LRx. Read More »

Diplomat Pharmacy Inc. recently announced that it will dispense opioid-overdose antidote naloxone without prescription to residents in Michigan via the company’s retail pharmacy at G-3320 Beecher Road in Flint. Read More »

Having disputed portions of Novartis’ patent for Gilenya (fingolimod), an immunosuppressant used to treat MS, New York City-based Argentum Pharmaceuticals LLC successfully obtained a special petition from the U.S. Patent & Trademark Office (PTO) recently. Read More »

A resubmitted Biologics License Application from California-based Portola Pharmaceuticals was recently deemed acceptable for review by the U.S. Food and Drug Administration and assigned an expected action due date of Feb. 2, 2018. Read More »

Takeda Pharmaceuticals Co. Limited recently announced that it will collaborate with Stanford University to form the Stanford Alliance for Innovative Medicines (Stanford AIM) to transform novel Stanford research into next-generation treatments for diseases. Read More »

After a comprehensive review, CVS Pharmacy has retained Community Pharmacy Accreditation from industry benchmark organization Utilization Review Accreditation Commission. Read More »

To improve access to medical treatment for far-flung Kansas residents, UnitedHealthcare Community Plan of Kansas recently presented several regional health care facilities with its Frontier Rural Health Care grants, ranging from $45,000 to $48,000 each. Read More »

Jerusalem-based Teva Pharmaceutical Industries Ltd. recently began marketing generic Axiron (testosterone) topical solution CIII, 30 mg/1.5 mL, in the United States for treating adult males who are experiencing low testosterone levels due to medical reasons. Read More »

An innovative treatment for certain types of acute lymphoblastic leukemia (ALL).1 — Pfizer’s Besponsa (inotuzumab ozogamicin) — recently obtained approval from the U.S. Food and Drug Administration via its Breakthrough Therapy designation and Priority Review programs. Read More »

Amgen and Humana Inc. will collaborate on finding opportunities to improve health outcomes by analyzing the real-world health care experiences of Humana's 13 million members. Read More »

Walgreens has been awarded the 2017 Infinity Arrow Award for Service and Take Back by the California Product Stewardship Council (CPSC) in recognition of the company’s Safe Medication Disposal program. Read More »

Using a non-invasive solution for obesity and other metabolic and gastrointestinal disorders, Minnesota’s EnteroMedics recently revealed that MedStar Health achieved its first implant device for a military veteran in Maryland via the Veterans Choice Program. Read More »

Trovagene Inc., a precision medicine biotechnology company, recently announced positive results from preclinical research of PCM-075 with a Histone deacetylase inhibitor in Non-Hodgkin Lymphoma cell lines. Read More »

Avella Specialty Pharmacy has been recognized by Inc. Magazine as one of the 5,000 fastest-growing companies in the United States. Read More »

The U.S. Food and Drug Administration has approved Ironwood Pharmaceuticals Inc.'s drug Duzallo, a once-daily oral treatment to fight hyperuricemia associated with gout in patients. Read More »

Biologics Inc., an oncology pharmacy services company under the McKesson Specialty Health umbrella, recently announced that Pfizer selected it to distribute Besponsa, a new IV therapy for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Read More »

Grifols, a provider of plasma-derived medicines, recently announced that its noninvasive workflow management system, Phocus Rx, is now used by three of the top five U.S. hospital information systems (HIS). Read More »

To promote its once-daily medication designed to address migraine headaches and seizures, Minnesota-based Upsher-Smith Laboratories recently launched its redesigned website for Qudexy XR (topiramate) extended-release capsules — along with a branded program allowing better product accessibility. Read More »

AstraZeneca and Merck & Co. Inc. recently announced that their collaborative PARP inhibitor, Lynparza, received approval from the U.S. Food and Drug Administration (FDA). Read More »